Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·Insights from the neuroscience of trauma · Insights from the neuroscience of trauma · Insights from the neuroscience of trauma ·
Research6 min read2026

Stellate Ganglion Block: A Paradigm Shift.

A procedure originally developed for chronic pain has produced one of the most striking response signals in PTSD literature. What it tells us about the disorder, and what comes next.

Ultrasound-guided stellate ganglion block procedure

For decades, the prevailing view of PTSD was psychological: a disorder of memory, cognition, and meaning, to be addressed with therapy and serotonergic medication. A growing body of clinical literature suggests a different framing, one rooted in the autonomic nervous system rather than the mind.

The signal comes from an unlikely source: anesthesiology.

A procedure with an unexpected effect

Stellate ganglion block (a brief, image-guided injection of local anesthetic into a cervical sympathetic structure) has been performed by anesthesiologists since the mid-twentieth century. Originally indicated for complex regional pain syndromes and certain vascular conditions, it remained a niche pain-medicine intervention for decades.

In the early 2000s, military physicians treating wounded service members began noticing something that wasn't in the textbook. After a stellate ganglion block performed for chronic pain, patients with co-existing PTSD reported, sometimes within hours, that their hypervigilance had eased, their sleep had improved, and their intrusive symptoms had dropped and in some cases dramatically.

A series of case reports became case series, became open-label studies, became randomized trials.

In a sham-controlled randomized trial (Rae Olmsted et al., JAMA Psychiatry, 2020, n = 113), stellate ganglion block reduced PTSD severity by 12.6 CAPS-5 points versus 6.1 with sham (effect size 0.56). Uncontrolled case series report response in 70 to 75% of patients (U.S. Department of Veterans Affairs Evidence Brief, 2017). The effect of a single block fades over weeks to months: that is why a durable implant is needed. A multisite, sham-controlled VA trial is under way; its results are not yet published.

Why it works

The stellate ganglion is the principal sympathetic relay for the upper body. Through it pass the fibers that govern heart rate, vascular tone, and the autonomic correlates of fight-or-flight. In a healthy nervous system, this signaling is contextual. It activates when needed and quiets when the threat passes.

In PTSD, it doesn't quiet.

The autonomic alarm remains chronically elevated. Cortisol patterns flatten. Heart rate variability collapses. The body keeps preparing for a threat that is no longer present. Mood, sleep, attention, and intrusive symptoms follow downstream.

A stellate ganglion block briefly interrupts that loop. The sympathetic outflow is paused. The autonomic system gets the chance to recalibrate, often producing rapid and meaningful symptom reduction. The intervention is reversible, repeatable, and remarkably well-tolerated.

The limitation

The benefit is real, but the delivery is not yet ready for primetime adoption.

The effect of a single block fades over weeks to months. Patients require repeat procedures, practical for a pain clinic, less so for a chronic psychiatric condition. Effects vary by injection technique, by operator, by depth and concentration of agent. The therapy is operator-dependent in ways that resist scale.

In short: a positive sham-controlled trial supports SGB for PTSD. Durable implant safety and efficacy remain to be demonstrated.

What comes next

Given the positive sham-controlled trial and response reported in uncontrolled case series, the natural question is whether continuous, programmable modulation of the same target could extend that response across years, while removing operator and pharmacology variables.

This is the bet behind a new generation of bioelectronic medicine.


The PTSD field is in the early stages of a shift in framing, from a disorder of thought to a disorder of physiology. The clinical evidence for autonomic intervention includes a positive sham-controlled trial and uncontrolled case series. The question is whether that intervention can be delivered durably, predictably, at scale, in a single procedure rather than recurring injections.

Stimalia is building toward that delivery. Device safety and efficacy in humans remain to be demonstrated.

References

  1. Rae Olmsted KL, Bartoszek M, Mulvaney S, et al. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(2):130-138.
  2. U.S. Department of Veterans Affairs, Evidence Synthesis Program. Evidence Brief: Effectiveness of Stellate Ganglion Block for Treatment of Posttraumatic Stress Disorder. February 2017.
  3. Stellate ganglion block for mental disorders: too good to be true? Scandinavian Journal of Pain. 2025.

Stimalia

Bioelectronic medicine · Louvain La Neuve · est. 2025